+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Viral Vectors Market by Application and Geography - Forecast and Analysis 2020-2024 - Product Image

Viral Vectors Market by Application and Geography - Forecast and Analysis 2020-2024

  • ID: 4860971
  • Report
  • November 2019
  • Region: Global
  • 154 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Batavia Biosciences BV
  • Cobra Biologics Ltd.
  • Creative Biogene
  • FinVector Oy
  • Lonza Group Ltd.
  • Merck KGaA
  • MORE
Global Viral Vectors Market: About this market
The viral vectors market analysis considers sales from both gene therapy and vaccines applications. Our study also finds the sales of viral vectors in Asia, Europe, North America, and ROW. In 2019, the gene therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as easy purification into high titers to mediate targeted gene delivery and its prolonged gene expression with nominal side effects will play a significant role in the gene therapy segment to maintain its market position. Also, our global viral vectors market report looks at factors such as rising prevalence of chronic diseases, increasing use of viral vectors to develop gene therapies and vaccines, and growing funding on and investments in gene therapies and vaccines. However, challenges associated with production and manufacturing of viral vectors, presence of stringent regulatory policies, and risks associated with viral vectors may hamper the growth of the viral vectors industry over the forecast period.

Global Viral Vectors Market: Overview

Rising prevalence of chronic disease
The development of therapies using viral vectors is in high demand due to the growing incidence of various life-threatening diseases such as diabetes, heart disease, HIV, cancer, and hemophilia A. Researchers are using viral vectors to develop curative therapies for cancer diseases such as bladder cancer, melanoma of the skin, lung and bronchus cancer, and other types of cancers. This is because viral vectors are a promising tool for the development of vaccines and gene therapy. Thus, the rising prevalence of chronic disease will lead to the expansion of the global viral vectors market at a CAGR of over 18% during the forecast period.

Emergence of novel technologies to manufacture viral vectors
The use of viral gene transfer vectors has increased owing to the approval of therapies, the initiation of late-stage clinical trials for the treatment of genetic disorders and multiple forms of cancer, and the need for the prevention of infectious diseases through vaccination. With an increased interest in and the widespread adoption of viral vectors by biopharmaceutical industries, there is a need to engineer safe and efficacious vectors and develop robust, scalable, and cost-effective production platforms for industrialization. Furthermore, adeno-associated virus vectors are among most commonly applied virus vectors for in vivo gene therapy as they can transduce non-dividing and dividing cells resulting in long-term and robust transgene expression. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape
With the presence of a few major players, the global viral vectors market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading viral vectors manufacturers, that include Asklepios BioPharmaceutical Inc., Batavia Biosciences BV, Cobra Biologics Ltd., Creative Biogene, FinVector Oy, Lonza Group Ltd., Merck KGaA, Novasep Holding SAS, Oxford Biomedica Plc, and Thermo Fisher Scientific Inc.

Also, the viral vectors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Batavia Biosciences BV
  • Cobra Biologics Ltd.
  • Creative Biogene
  • FinVector Oy
  • Lonza Group Ltd.
  • Merck KGaA
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
  • Value chain analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY APPLICATION
  • Market segmentation by application
  • Comparison by application
  • Gene therapy - Market size and forecast 2019-2024
  • Vaccines - Market size and forecast 2019-2024
  • Market opportunity by application
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Increasing number of R&D activities for development of gene therapies
  • and vaccines using viral vectors
  • Rising number of M&A and collaborations
  • Emergence of novel technologies to manufacture viral vectors
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Asklepios BioPharmaceutical Inc.
  • Batavia Biosciences BV
  • Cobra Biologics Ltd.
  • Creative Biogene
  • FinVector Oy
  • Lonza Group Ltd.
  • Merck KGaA
  • Novasep Holding SAS
  • Oxford Biomedica Plc
  • Thermo Fisher Scientific Inc.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Vendors: Key offerings
Exhibit 02: Global healthcare market
Exhibit 03: Segments of global healthcare market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2019
Exhibit 18: Application - Market share 2019-2024 (%)
Exhibit 19: Comparison by application
Exhibit 20: Gene therapy - Market size and forecast 2019-2024 ($ millions)
Exhibit 21: Gene therapy using adenovirus vectors
Exhibit 22: Gene therapy using adeno-associated virus vectors
Exhibit 23: Gene therapy using lentivirus vectors
Exhibit 24: Gene therapy - Year-over-year growth 2020-2024 (%)
Exhibit 25: Vaccines - Market size and forecast 2019-2024 ($ millions)
Exhibit 26: Vaccines - Year-over-year growth 2020-2024 (%)
Exhibit 27: Market opportunity by application
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2019-2024 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America - Market size and forecast 2019-2024 ($ millions)
Exhibit 32: North America - Year-over-year growth 2020-2024 (%)
Exhibit 33: Top 3 countries in North America
Exhibit 34: Europe - Market size and forecast 2019-2024 ($ millions)
Exhibit 35: Europe - Year-over-year growth 2020-2024 (%)
Exhibit 36: Top 3 countries in Europe
Exhibit 37: Asia - Market size and forecast 2019-2024 ($ millions)
Exhibit 38: Asia - Year-over-year growth 2020-2024 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW - Market size and forecast 2019-2024 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2020-2024 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: Asklepios BioPharmaceutical Inc. - Vendor overview
Exhibit 52: Asklepios BioPharmaceutical Inc. - Product segments
Exhibit 53: Asklepios BioPharmaceutical Inc. - Organizational developments
Exhibit 54: Asklepios BioPharmaceutical Inc. - Key offerings
Exhibit 55: Asklepios BioPharmaceutical Inc. - Key customers
Exhibit 56: Batavia Biosciences BV - Vendor overview
Exhibit 57: Batavia Biosciences BV - Product segments
Exhibit 58: Batavia Biosciences BV - Organizational developments
Exhibit 59: Batavia Biosciences BV - Key offerings
Exhibit 60: Batavia Biosciences BV - Key customers
Exhibit 61: Cobra Biologics Ltd. - Vendor overview
Exhibit 62: Cobra Biologics Ltd. - Product segments
Exhibit 63: Cobra Biologics Ltd. - Organizational developments
Exhibit 64: Cobra Biologics Ltd. - Key offerings
Exhibit 65: Cobra Biologics Ltd. - Key customers
Exhibit 66: Creative Biogene - Vendor overview
Exhibit 67: Creative Biogene - Business segments
Exhibit 68: Creative Biogene - Key offerings
Exhibit 69: Creative Biogene - Key customers
Exhibit 70: FinVector Oy - Vendor overview
Exhibit 71: FinVector Oy - Service segments
Exhibit 72: FinVector Oy - Key offerings
Exhibit 73: FinVector Oy - Key customers
Exhibit 74: Lonza Group Ltd. - Vendor overview
Exhibit 75: Lonza Group Ltd. - Business segments
Exhibit 76: Lonza Group Ltd. - Organizational developments
Exhibit 77: Lonza Group Ltd. - Geographic focus
Exhibit 78: Lonza Group Ltd. - Segment focus
Exhibit 79: Lonza Group Ltd. - Key offerings
Exhibit 80: Lonza Group Ltd. - Key customers
Exhibit 81: Merck KGaA - Vendor overview
Exhibit 82: Merck KGaA - Business segments
Exhibit 83: Merck KGaA - Organizational developments
Exhibit 84: Merck KGaA - Geographic focus
Exhibit 85: Merck KGaA - Segment focus
Exhibit 86: Merck KGaA - Key offerings
Exhibit 87: Merck KGaA - Key customers
Exhibit 88: Novasep Holding SAS - Vendor overview
Exhibit 89: Novasep Holding SAS - Business segments
Exhibit 90: Novasep Holding SAS - Organizational developments
Exhibit 91: Novasep Holding SAS - Key offerings
Exhibit 92: Novasep Holding SAS - Key customers
Exhibit 93: Oxford Biomedica Plc - Vendor overview
Exhibit 94: Oxford Biomedica Plc - Business segments
Exhibit 95: Oxford Biomedica Plc - Organizational developments
Exhibit 96: Oxford Biomedica Plc - Geographic focus
Exhibit 97: Oxford Biomedica Plc - Segment focus
Exhibit 98: Oxford Biomedica Plc - Key offerings
Exhibit 99: Oxford Biomedica Plc - Key customers
Exhibit 100: Thermo Fisher Scientific Inc. - Vendor overview
Exhibit 101: Thermo Fisher Scientific Inc. - Business segments
Exhibit 102: Thermo Fisher Scientific Inc. - Organizational developments
Exhibit 103: Thermo Fisher Scientific Inc. - Geographic focus
Exhibit 104: Thermo Fisher Scientific Inc. - Segment focus
Exhibit 105: Thermo Fisher Scientific Inc. - Key offerings
Exhibit 106: Thermo Fisher Scientific Inc. - Key customers
Exhibit 107: Validation techniques employed for market sizing
Exhibit 108: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Batavia Biosciences BV
  • Cobra Biologics Ltd.
  • Creative Biogene
  • FinVector Oy
  • Lonza Group Ltd.
  • Merck KGaA
  • MORE
The following companies as the key players in the global viral vectors market: Asklepios BioPharmaceutical Inc., Batavia Biosciences BV, Cobra Biologics Ltd., Creative Biogene, FinVector Oy, Lonza Group Ltd., Merck KGaA, Novasep Holding SAS, Oxford Biomedica Plc, and Thermo Fisher Scientific Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the emergence of novel technologies to manufacture viral vectors.”

According to the report, one of the major drivers for this market is the rising prevalence of chronic disease.

Further, the report states that one of the major factors hindering the growth of this market is the challenges associated with production and manufacturing of viral vectors.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Asklepios BioPharmaceutical Inc.
  • Batavia Biosciences BV
  • Cobra Biologics Ltd.
  • Creative Biogene
  • FinVector Oy
  • Lonza Group Ltd.
  • Merck KGaA
  • Novasep Holding SAS
  • Oxford Biomedica Plc
  • Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown
Adroll
adroll